Herein, we report that GRB7 plays a pivotal role in MEKi resistance in CRC cells with KRAS mutations by performing unbiased genome-wide CRISPR/Cas9 knockout screening, which is a powerful approach to identifying synergistic drug targets [35]. This evidence concerns the gene GRB7 and colorectal carcinoma.